Ocrelizumab accepted for EMA review
Ocrelizumab accepted for EMA review
Roche has announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of ocrelizumab for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in the European Union (EU)...Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 12404 Views
-
Last post by NHE
-
- 0 Replies
- 1185 Views
-
Last post by NHE
-
- 0 Replies
- 1951 Views
-
Last post by frodo
-
- 0 Replies
- 1251 Views
-
Last post by frodo
-
- 0 Replies
- 2118 Views
-
Last post by NHE
-
- 0 Replies
- 1700 Views
-
Last post by frodo
-
- 0 Replies
- 1325 Views
-
Last post by NHE
-
- 1 Replies
- 1801 Views
-
Last post by frodo
-
- 0 Replies
- 2552 Views
-
Last post by NHE